Effects of combination treatment with alendronate and vitamin K2 on bone mineral density and strength in ovariectomized mice

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 4, 2010, Pages 403-409

  Sasaki, Hiroshi ^a   Miyakoshi, Naohisa ^a   Kasukawa, Yuji ^a   Maekawa, Shigeto ^a   Noguchi, Hideaki ^a   Kamo, Keji ^a   Shimada, Yoichi ^a  

^a AKITA UNIVERSITY   (Japan)

Author keywords

Alendronate; Bone mineral density; Bone strength; Ovariectomized mice; Vitamin K2

Indexed keywords

ALENDRONIC ACID; MENATETRENONE; BONE DENSITY CONSERVATION AGENT; FARNOQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DEMINERALIZATION; BONE DENSITY; BONE STRENGTH; BONE TURNOVER; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GEOMETRY; LOAD CARRYING CAPACITY; MONOTHERAPY; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ANIMAL; BIOMECHANICS; C57BL MOUSE; DRUG EFFECTS; FEMUR; OSTEOPOROSIS;

ALENDRONATE; ANIMALS; BIOMECHANICS; BODY WEIGHT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FEMUR; MICE; MICE, INBRED C57BL; OSTEOPOROSIS; OVARIECTOMY; VITAMIN K 2; BIOMECHANICAL PHENOMENA;

EID: 77956456573     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-009-0148-5     Document Type: Article

References (28)

1. Colucci S, Minielli V, Zambonin G, Cirulli N, Mori G, Serra M, Patella V, Zambonin Zallone A, Grano M (1998) Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 63:230-235
2. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M (1995) Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone (NY) 16:235-245
3. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443
4. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109-3115
5. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124
6. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610
7. Li J, Mashiba T, Burr DB (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69:281-286
8. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone (NY) 28:524-531
9. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620
10. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301
11. 2 promotes 1alpha, 25(OH)2 vitamin D3-induced mineralization in human periosteal osteoblasts. Calcif Tissue Int 59:466-473
12. 2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 278:43919-43927
13. 2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15:515-521
14. Ishida Y, Kawai S (2004) Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfa-calcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi osteoporosis prevention study. Am J Med 117:549-555
15. Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ (2006) Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 166:1256-1261
16. 2 (menatetrenone) and alendronate on bone mineral density and bone strength in rats fed a low-magnesium diet. Bone (NY) 35:1136-1143
17. Kasukawa Y, Baylink DJ, Wergedal JE, Amaa Y, Srivastava AK, Guo R, Mohan S (2003) Lack of insulin-like growth factor I exaggerates the effect of calcium deficiency on bone accretion in mice. Endocrinology 144:4682-4689
18. 2 and risedronate on long bone mass in hypophysectomized young rats. Exp Anim 56:103-110
19. 2 on the development of osteopenia in rats as the models of osteoporosis. Yonsei Med J 47:157-166
20. 2. J Bone Miner Metab 25:12-18
21. Andersson N, Surve VV, Lehto-Axtelius D, Ohlsson C, Håkanson R, Andersson K, Ryberg B (2002) Drug-induced prevention of gastrectomy- and ovariectomy-induced osteopaenia in the young female rat. J Endocrinol 175:695-703
22. 2 further increases bone volume and ameliorates extremely low turnover bone induced by bisphosphonate therapy in tail-suspension rats. J Bone Miner Metab 21:154-160
23. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285:785-795
24. 2 on threedimensional trabecular microarchitecture in ovariectomized rats. J Bone Miner Res 15:1810-1817
25. 2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporosis Int 18:963-972
26. Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps RJ, Zhou X, Sibonga JD, Turner RT (2006) Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone (NY) 39:345-352
27. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone (NY) 27:687-694
28. Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R, Phipps R, Klaushofer K (2006) Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 21:1581-1590